Nicholas Spiliotes is Co-Chair of the firm's Finance Department and has over 25 years of experience in international project finance, cross-border corporate transactions in emerging markets and domestic general corporate matters. He has particular expertise in the energy, financial services, and information technology sectors. He has served as lenders' or investors' counsel on projects in Turkey, India, Qatar, Egypt, Colombia, Guatemala, Rwanda, Uganda, Zambia, and Afghanistan. On the domestic side, he advises clients on renewable energy project financings, credit card and receivables programs and transactions, services contracts, and general corporate matters.
Mr. Spiliotes has decades of experience advising clients on national security compliance matters involving foreign investment approvals (CFIUS); Department of Defense and Department of Energy foreign investment approvals under the National Industrial Security Program; and U.S. sanctions and embargoes (OFAC), including certain enforcement matters, relating to a broad range of industries, products and transactions.
From 2004 to 2007, Mr. Spiliotes served as Chair of Morrison & Foerster's 520 lawyer Business Department. He served as firm-wide Managing Partner for Operations from 1997 to 2000, and as Managing Partner of the Washington, D.C. office from 1995 to 1997.
Prior to joining the firm, Mr. Spiliotes served in the U.S. government as a junior staff member of the National Security Council at the White House, and in the U.S. Foreign Service as a Special Assistant in the Office of the U.S. Representative to the United Nations.
SoftBank Group Corp. / Sprint Corporation
Advise SoftBank Group Corp. on U.S. national security matters, including with respect to the Committee on Foreign Investment in the United States in connection with SoftBank’s acquisition of Sprint Corporation and ongoing regulatory matters. (2013 to date)
Export-Import Bank of the United States / Ecopetrol S.A. of Colombia
Represent U.S. Ex-Im Bank in a $420 million long-term and a $427 million medium-term financing for the export of U.S. oil and gas equipment to Ecopetrol for upgrading its Barrancabermeja Refinery and for use throughout the Ecopetrol pipeline distribution system. (2011-2013)
India / U.S. Life Sciences Strategic Alliance
Represent Indian pharmaceutical company in strategic alliance with U.S. Nasdaq-listed company, and client investment in U.S. Co.; entered into $50 million joint venture in India with U.S. Co. for research and development, manufacturing and marketing in India of vaccines, pharmaceuticals, and biologic diagnostic products. (2009)
India International Arbitration
Successfully settled an international arbitration on favorable terms for our client. The dispute involved the law of three jurisdictions (England, Mauritius, and India) and minority shareholder rights. (2007-2009)
Qatar / Polysilicon Purification Project
Represent U.S. developer and co-counsel to Qatar project company in the development of $550 million photovoltaic polysilicon purification plant, including negotiation of joint venture agreements, project contracts, and related matters. (2007-2009)
Alaska Gas Pipeline Joint Venture
Represent State of Alaska in negotiations to form a joint venture with major Alaska North Slope producers to develop a $30 billion pipeline bringing Alaskan gas through Canada to the lower 48 states. Develop financing plan, including possible use of U.S. government guarantees. (2004-2006)
Turkish Power Projects
Since 1995, represent export credit agency lenders in over $2.5 billion of financings for five power projects in Turkey, providing over 20% of the country's installed electrical capacity. Also, represent export credit agencies in financing power projects in Columbia and Guatemala.
Telecommunications Corporate Joint Venture
Represent developer in $100 million wireless telecommunications corporate joint venture with Afghan Ministry of Communications. (2004-2005)
U.S. / Uganda Infectious Disease Research Facility
Represent U.S. developer of $4 million university-based infectious disease clinic in Kampala, Uganda with financing from U.S. pharmaceutical company. (2002-2003)